Guided Therapeutics, Inc. (GTHP)
| Previous close | 0.0916 |
| Open | 0.1100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0956 - 0.1100 |
| 52-week range | 0.0620 - 0.3000 |
| Volume | |
| Avg. volume | 24,175 |
| Market cap | 5.339M |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireLeading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results
PEACHTREE CORNERS, Ga., February 20, 2024--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that a group of prominent cervical cancer doctors are in the final stages of completing the clinical data report that will be submitted for approval by the Chinese National Medical Products Administration (NMPA). The data quality assurance review team is being led by Dr. Sui Long, Director of the Gynecology Hospital at Fudan University and includes p
Business WireGuided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval
PEACHTREE CORNERS, Ga., November 20, 2023--Guided Therapeutics, Inc. (OTCQB: GTHP) announced today the completion of the clinical trial for marketing and sales approval of the Company’s LuViva Advanced Cervical Scan by the Chinese National Medical Products Administration (NMPA). The study, which included approximately 450 women, was conducted at four prestigious medical institutions, including Shandong University, Fudan University and Peking University. The study was led by Professor Dr. Kong Be
Business WireGuided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval
PEACHTREE CORNERS, Ga., May 01, 2023--Guided Therapeutics, Inc. or the "Company" (OTCQB: GTHP), the maker of LuViva, a rapid and painless cervical cancer detection system based on the Company’s patented biophotonic technology, provided an update regarding the start of its pivotal clinical trial. The results of this clinical study will be used to support the Company’s application for U.S. FDA approval. The clinics involved in the study represent a mix of academic and community practices as well a
